Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

TACLONEX

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

Standard Dose
0.064%;0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TACLONEX is listed in Drugs@FDA under application 022185 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE Form and strength SUSPENSION;TOPICAL - 0.064%;0.005% Sponsor LEO PHARMA AS Submission history Latest submission status date: 2019-07-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview TACLONEX is listed in Drugs@FDA under application 022185 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE Form and strength SUSPENSION;TOPICAL - 0.064%;0.005% Sponsor LEO PHARMA AS Submission history Latest submission status date: 2019-07-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
TACLONEX (BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE) | Drug Monograph | MedicHelpline